Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors

Summary

This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).

Timeline

Start

2024-09-11

Primary completion

2025-12-31

Completion

2026-12-30

Drugs

Indications